NewsDialy
Georg Schett, the German scientist who spent five years demonstrating that CAR-T therapy, a treatment that engineers a patient's own immune cells to target and eliminate the source of disease, can reset the immune system in autoimmune patients, is co-founding his first biotech company.
The new company plans to work with antibody therapies and has no immediate plans to pursue CAR-T, the area where Schett built his standing.
How Schett got here Over the last five years, Schett's work in autoimmune disease attracted steady attention from industry.
He became a scientific adviser across roughly half a dozen startups, the sort of expert whose name companies in the space felt they needed on their advisory boards.
Keep reading